GlaxoSmithKline (GSK) announced the presentation of new data on fluticasone furoate nasal spray (FFNS), an enhanced affinity intranasal corticosteroid (INS) currently in development for use in the treatment of allergic rhinitis.
The Food and Drug Administration (FDA) today approved Humira (adalimumab) to treat adult patients with moderately to severely active Crohn’s disease, a chronic inflammatory disease of the intestines, which affects an estimated one million Americans.
AstraZeneca (NYSE: AZN) announced the commencement of a new Phase III study of its new investigational once-daily orally administered drug, vandetanib (ZACTIMA(R), ZD6474).
When it comes to lowering cholesterol levels, garlic stinks, according to a new study from the Stanford University School of Medicine.
Three forms of garlic — including raw garlic and two types of commercial garlic supplements — did not significantly reduce low-density lipoprotein (LDL or “bad”) cholesterol during a six-month trial, according to results published in the Feb. 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
New research suggests that gene therapy is a safe treatment method to explore in patients whose lower limbs are at risk for amputation because of poor circulation caused by blocked blood vessels.
A Georgetown medical professor cuts through hype surrounding weight-loss supplements with new science-based guide.
The U.S. Food and Drug Administration (FDA) has approved the antidepressant Cymbalta(R) (duloxetine HCl) for the treatment of generalised anxiety disorder (GAD), Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim announced today.
AstraZeneca announced the commencement of a new Phase III study of its new investigational once-daily orally administered drug, vandetanib (ZACTIMA(R), ZD6474).
Shire plc and its collaborative partner New River Pharmaceuticals Inc., announce the U.S. Food and Drug Administration has granted marketing approval for VYVANSE (lisdexamfetamine dimesylate, formerly known as NRP104), for the treatment of attention deficit hyperactivity disorder. VYVANSE is a prodrug that is therapeutically inactive until metabolized in the body.